What is it with the A's and biomeds, this is the collaborator for other immunology
The numbers in the study, are not high enough to allow statistical significance
As for HSV2, Business as usual. There was enough info/response to warrant continuation.
Fine tune delivery and dosage.
One group seemed to do a lot better than the other, based on delivery.
No fireworks, but business as usual.
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-22
-
- There are more pages in this discussion • 329 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.68 |
Change
0.680(4.53%) |
Mkt cap ! $331.4M | |||
| Open | High | Low | Value | Volume |
| $14.90 | $15.75 | $14.85 | $431.9K | 28.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $15.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.95 | 300 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |